Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Size And Revenue Outlook Through 2030
The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market has seen significant expansion in recent years. Its value is forecast to rise from $1.27 billion in 2025 to $1.48 billion in 2026, at a compound annual growth rate (CAGR) of 16.7%. Historically, this growth can be attributed to several factors including the increasing prevalence of cancer, breakthroughs in next-generation sequencing, a rising demand for non-invasive diagnostic methods, expanding research into genomic biomarkers, and supportive regulatory environments for precision medicine.
The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market size is set for significant expansion in the coming years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. This growth during the forecast period can be attributed to the adoption of AI-powered genomic analysis, the expansion of personalized oncology programs, integration with hospital information systems, increasing investments in ctDNA panels, and the demand for real-time treatment monitoring. Prominent trends anticipated in the forecast period include personalized ctDNA assay development, longitudinal cancer monitoring, integration with clinical decision support systems, non-invasive disease tracking, and AI-driven mutation analysis.
Get A Free Sample Report With In-Depth Market Insights:
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Growth Momentum: What Factors Are Shaping Demand?
The escalating incidence of cancer is anticipated to drive the expansion of the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market in the foreseeable future. Cancer is characterized by a group of diseases involving the unchecked propagation of aberrant cells, which possess the capability to invade adjacent tissues and disseminate throughout the body. The rise in cancer cases is attributable to several factors, including extended lifespans, enhanced capabilities for early diagnosis, and advancements in therapy that enable patients to live longer with the condition. Personalized circulating tumor DNA fingerprint panels play a crucial role in cancer management by facilitating prompt identification, continuous oversight, and accurate regulation of tumor progression, thereby enhancing patient survival rates and guiding specific treatment approaches. For instance, in October 2025, the American Cancer Society, a US-based nonprofit organization dedicated to cancer research and advocacy, reported approximately 18.6 million cancer survivors in the US, constituting slightly more than 5% of the population, with forecasts indicating an increase to 22 million by 2035. Consequently, the growing prevalence of cancer is a key factor propelling the growth of the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market.
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Segments: Where Is Growth Concentrated?
The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market covered in this report is segmented –
1) By Product Type: Single Gene Panels, Multi Gene Panels, Comprehensive Genomic Panels
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer, Hematological Malignancy
3) By Technology: Next Generation Sequencing, Polymerase Chain Reaction Based, Other Technologies
4) By Application: Oncology, Non Invasive Prenatal Testing, Transplantation, Other Applications
5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Single Gene Panels: Tumor Specific Mutation Panels, Actionable Mutation Panels, Hereditary Cancer Panels
2) By Multi Gene Panels: Targeted Cancer Panels, Disease Specific Panels, Therapy Guidance Panels
3) By Comprehensive Genomic Panels: Pan Cancer Panels, Whole Exome Panels, Whole Genome Panel
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Trends Redefining Industry Growth
Leading companies within the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market are concentrating on developing highly sensitive, tumor-informed genome-based assays. These advancements aim to improve early cancer detection, monitor patient response to treatment, and identify molecular residual disease (MRD) with greater accuracy. Such ultra-sensitive, tumor-informed, genome-based assays are sophisticated molecular diagnostic tools designed to identify and track specific tumor mutations in patients, thereby enabling the detection of extremely minute quantities of circulating tumor DNA (ctDNA) in the bloodstream. For example, in April 2025, Natera Inc., a US-based molecular diagnostics company, announced the extensive clinical launch of its ultra-sensitive Signatera Genome MRD test. This test employs whole-genome sequencing (WGS) to create highly individualized ctDNA fingerprint panels, custom-designed to each patient’s specific tumor profile. This method significantly increases the number of tumor variants that can be tracked and enhances detection sensitivity even at ultra-low ctDNA levels. This innovation strengthens MRD monitoring capabilities across numerous cancer types, supporting earlier intervention and facilitating more informed treatment decisions.
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the personalized circulating tumor deoxyribonucleic acid (ctdna) fingerprint panels market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Burning Rock Biotech Limited, Personalis Inc., Biodesix Inc., OneCell Diagnostics Pvt. Ltd., CD Genomics, Creative Biolabs Inc., Predicine Inc., BioCreatrix Pte. Ltd., OncoDNA SA, Lucence Diagnostics Pte Ltd., Singlera Genomics Inc., Nonacus Ltd.
View The Full Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Report:
Personalized Circulating Tumor Deoxyribonucleic Acid (ctDNA) Fingerprint Panels Market Geographic Distribution And Regional Opportunities
North America was the largest region in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
